Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line treatment in high-risk HIV-related diffuse large B-cell non-Hodgkin lymphoma with early high-dose chemotherapy and autologous stem cell transplantation
2006-006047-30Phase 2Terminated
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Nov 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in diffuse large B-cell lymphoma (DLBCL) and human immunodeficiency virus infection (HIV), sponsored by ASST Spedali Civili di Brescia. Primary endpoints: complete remission, disease-free survival and 1 more. Started Nov 2007; status: terminated.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2006-006047-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006047-30.